AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00736528
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 14 days
Trial: NCT03651661
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo administered as nasal spray
Trial: NCT04204252
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparation of NaCl in phosphate buffer solution with 0.01% TWEEN-80
Trial: NCT01655680
Drug: ABT-126
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-126 Middle Dose
Trial: NCT01655680
Drug: ABT-126
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-126 Low Dose
Trial: NCT01655680
Drug: ABT-126
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-126 High Dose
Trial: NCT01655680
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03150160
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drop applied topically to the affected eye(s) in the morning and evening
Trial: NCT00199069
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00199069
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02779582
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pill with no effect
Trial: NCT00199069
Drug: Dexamethasone / Prednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03245489
Drug: acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 81mg/day oral
Trial: NCT00171782
Drug: VALSARTAN+HYDROCHLOROTHIAZIDE
RxNorm normalized name: hydrochlorothiazide / valsartan
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01514266
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04033939
Drug: HSK3486
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04033939
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03569631
Drug: BPN14770
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg BPN14770 capsules
Trial: NCT03569631
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules to mimic 25 mg BPN14770 capsules
Trial: NCT01298531
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo subcutaneous (SC) injections once weekly for 8 weeks.
Trial: NCT03024879
Drug: Erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01785420
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A 90 minute intravenous infusion of saline as placebo
Trial: NCT00016159
Drug: tretinoin
RxNorm normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01034137
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: orally weekly in ascending dosages, starting at 10mg/week
Trial: NCT01034137
Drug: placebo MTX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally weekly
Trial: NCT00005583
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01451905
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo pens contain saline and are administered in the same way and volume as Victoza. The placebo pens are specially prepared for this study and will be used in the study only
Trial: NCT03649633
Drug: Stress-dose Hydrocortisone plus Vitamin C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of septic shock with vitamin C and stress-dose hydrocortisone aimed at the attenuation of the systemic inflammatory response and the improvement of vasopressor responsiveness.
Trial: NCT00162383
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01562158
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02213042
Drug: Aromatase Inhibitors (AIs)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects who were hormone receptor-positive were required to receive an aromatase inhibitor as combination treatment; however the choice of the aromatase inhibitor selected for each patient was determined by the patients' investigator. The AIs the Investigator could choose from were anastrozole, exemestane, and letrozole and dosing was per product information.
Trial: NCT00559754
Drug: Standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As prescribed
Trial: NCT02540226
Drug: Intravenous saline
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02540226
Drug: Topical saline
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03634644
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mainly composed of corn oil
Trial: NCT02215031
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00576979
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT05428293
Drug: A1: Ibuprofen/Acetaminophen Fixed dose combination oral suspension (Laboratorios Silanes S.A. de C.V.)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formula : 100 mg/ 125 mg /5mL Pharmaceutical Form: Oral suspension Dosage: 5mL (100 mg/125mg) Administration way: oral
Trial: NCT05428293
Drug: A2: Ibuprofen (Advil®, Pfizer S.A. de C.V.)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical Form: oral suspension Formula: 2 g/100 mL Dosage: 5 mL(100 mg of Ibuprofen) Administration way: oral
Trial: NCT05428293
Drug: A3: Acetaminophen (Tylenol®, from Janssen-Cilag, S.A. de C.V.)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical Form: oral suspension Formula: 3.2 g/100 mL Dosage: 3.9 mL (125 mg) Administration way: oral
Trial: NCT00535366
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral inhalation from MDI
Trial: NCT02557945
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be treated with 400mg pills of placebo, titrating up to 3600mg per day, or 9 tablets (3 tabs tid)
Trial: NCT03712969
Drug: Shenlingcao Oral Liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive Shenlingcao oral liquid combined with conventional adjuvant chemotherapy, which take 4 courses, 30 days per course, one bottle per day.
Trial: NCT02269202
Drug: Crobenetine, i.v. infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02269202
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01100684
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01649609
Drug: Mycophenolate acid
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Myfortic or CellCept - The standard of care immunosuppression treatment most commonly used for renal transplant patients
Trial: NCT00447603
Drug: hydrochlorothiazide (+) losartan potassium
RxNorm normalized name: hydrochlorothiazide / losartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: losartan/hydrochlorothiazide 12.5mg tablet po qd; for a 4 week study period.
Trial: NCT02148107
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00734123
Drug: Simvastatin or Atorvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin 10-40 mg or Atorvastatin 20-40 mg will be prescribed according to LDL cholesterol reduction target.
Trial: NCT01381900
Drug: Sulphonylurea
RxNorm normalized name: metformin and sulfonylureas
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participant's stable dose of background therapy of metformin plus sulphonylurea should be continued throughout the study.
Trial: NCT04248855
Drug: KAN-101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) infusion
Trial: NCT04248855
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) infusion
Trial: NCT00185068
Drug: Olmesartan medoxomil/hydrochlorothiazide
RxNorm normalized name: olmesartan medoxomil/hydrochlorothiazide 40 mg-25 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02025166
Drug: lornoxicam
RxNorm normalized name: lornoxicam
DrugBank: Lornoxicam (DB06725)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pain treatment with NSAID (lornoxicam) at the time of the procedure
Trial: NCT00374543
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered daily for 8 weeks
Trial: NCT01185821
Drug: BAF312
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAF312 was supplied in film-coated tablets in strengths of 5, 4 ,2, 1, .5 and .25 mg. The actual doses taken were 10, 2, 1.25, .5 and .25 mg taken orally once a day.
Trial: NCT02605785
Drug: F-18 AV 1451
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tau PET scan
Trial: NCT02835560
Drug: Esoprazole antisecretory drug of each quadruple therapy Esoprazole-based quadruple therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esoprazole -based quadruple therapy for 14 days: Esoprazole 20mg bid, Bismuth Potassium Citrate 220mg bid, Amoxicillin 1000mg bid, Clarithromycin 500mg bid
Trial: NCT01474369
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-438 placebo-matching tablets, orally, once daily for 5 weeks.
Trial: NCT00515736
Drug: Selenium (Se), Zinc (Zn), Vitamin C, Vitamin B1, Vitamin E
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Se 270mcg, Zn 30mg, C 1.1g, B1 100mg, E 300mg
Trial: NCT00515736
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vehicle
Trial: NCT01140373
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Three cohorts of patients each will receive escalating doses of transduced autologous chimeric T lymphocytes at 1 x 10\^7 CAR+ T cells/kg, 3 x 10\^7 CAR+ T cells/kg, and 1 x 10\^8 CAR+ T cells/kg, respectively. One patient will be initially added to the three already enrolled in cohort 1 using a new variant vector expressing the P28z CAR, and up to three patients may be added to each cohort, for a total of up to six each, in the case of Grade 3 toxicity and/or sub-optimal imaging. A 4th cohort of three patients may be added if an anti-PSMA effect is observed either immunologically or radiographically or if there is preferential targeting of the cells at a particular dose level. The dose level of the 4th cohort would be from a previously tested dose level. All patients will receive one dose of cyclophosphamide (Cy) at 300mg/m2 iv one day prior to infusion of T cells.
Trial: NCT01509508
Drug: Immediate ARV treatment initiation with TDF/FTC/EFV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All HIV-infected adults will be offered ART regardless of their immunological and clinical staging.~The first line regimen proposed will be Atripla (R), a fixed dose combination containing tenofovir disoproxil (245 mg)/emtricitabine (200 mg)/efavirenz (600 mg)(FTC/TDF/EFV). The dosing will be 1 tablet OD.
Trial: NCT02400320
Drug: Topical Spray
RxNorm normalized name: Topical Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical spray containing Diclofenac 1.16%, Linseed Oil 3%, Menthol 5%, Methyl salicylate 10%.
Trial: NCT02400320
Drug: Topical Gel
RxNorm normalized name: Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical gel containing Diclofenac 1.16%, Menthol 5%, Methyl salicylate 10%
Trial: NCT00000328
Drug: Opioid-Related Disorders
RxNorm normalized name: DRUGS FOR ACID RELATED DISORDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04096391
Drug: Pain Medicine
RxNorm normalized name: Night Time Pain Medicine Extra Strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injections, spinal cord stimulation, peripheral nerve stimulation, pain medication, etc.
Trial: NCT03341273
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin is an azalide antibiotic and is derived from erythromycin used to treat many different types of infections caused by bacteria, such as respiratory infections.
Trial: NCT01567215
Drug: Steroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dermovate creme group IV steroid. Application 2 times a day for 3 weeks or less if the granuloma disappears.
Trial: NCT04052971
Drug: ABN401- Expansion Phase
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose administration: Expansion Phase The expansion phase of the study will use the dose and schedule determined to be most appropriate in the dose escalation portion of the study. This may be the MTD and/or the RP2D and will consist of cohorts of NSCLC patients with c-MET dysregulation.~Patients will receive ABN401 800 mg, administered orally once daily for 21 days until disease progression, unacceptable toxicity, or patient withdrawal.
Trial: NCT04193059
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: cyclophosphamide 600 mg/m\^2 iv d1, 21 days per cycle, 4 cycles.
Trial: NCT01861106
Drug: Cyclophosphamide (CTX, Cytoxan)
RxNorm normalized name: cyclophosphamide Oral Tablet [Cytoxan]
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 14.5 mg/kg IV (in the vein) infusion over 30 minutes once daily on days -6 and -5 (weight based dosing) or 50 mg/kg IV infusion over 2 hours on day -6 (weight based dosing). For post-transplant, 50/kg IV once daily x2 doses on days +3 and +4
Trial: NCT00588770
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04002947
Drug: DA-EPOCH
RxNorm normalized name: Epoch Blemish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vincristine 1.4 mg/m2 (2 mg cap) IV on Day 1, Doxorubicin 10 mg/m2/day CIVI on Days 1-4, Etoposide 50 mg/m2/day CIVI on Days 1-4, Cyclophosphamide 750 mg/m2 IV on Day 5. Prednisone 60 mg/m2 PO BID is administered daily on Days 1-5 of each cycle. Each cycle is 21 days and drugs will be given for 6 cycles.
Trial: NCT01527318
Drug: Fibrate treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive a dosage of 400mg Bezafibrate every day during 28 weeks
Trial: NCT04364048
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemoradiation will be with platinum-based chemotherapy (cisplatin or carboplatin, with etoposide, taxane, or pemetrexed) selected at the treating physician's discretion. The chemotherapy regimen used should be administered per institutional standards following the prescribing guidelines for each drug
Trial: NCT03509831
Drug: INT-2150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Period: INT-2150~2. Period: Irsogladine maleate 2 mg+Nizatidine 150 mg
Trial: NCT02517359
Drug: RV6153 matching placebo 14 day repeat dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safety and tolerability of repeat doses
Trial: NCT02517359
Drug: RV6153 matching placebo 28 day repeat dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safety and tolerability of repeat doses
Trial: NCT01773772
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will take oral placebo suspension at 1600 h and again at 2000 h.
Trial: NCT00174811
Drug: telithromycin (HMR3647)
RxNorm normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01736020
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01952574
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by study site staff once a month (QM) as a subcutaneous injection
Trial: NCT01371630
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00665522
Drug: fentanyl iontophoretic transdermal system (40mcg) No Placebo
RxNorm normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 40 mcg per dose, maximum of 6 doses/hour
Trial: NCT00665522
Drug: IV PCA with standard of care opioid analgesia
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: total maximum 80 doses/24 hours
Trial: NCT01371630
Drug: Mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01371630
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IT, IV, and PO
Trial: NCT03276910
Drug: EPREX
RxNorm normalized name: Eprex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 doses at 50 IU/kg or 20 IU/kg in subcutaneous use
Trial: NCT01712412
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00410410
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline, IV, 0 mg/kg, every 28 days.~Induction Period 3 months~Maintenance Period 12 months
Trial: NCT02795793
Drug: Non-operative management group (NOM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: With intravenous Piperacillin with Tazobactam (Tazocin)
Trial: NCT04490239
Drug: Intranasal heparin sodium (porcine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal heparin sodium
Trial: NCT01753102
Drug: Estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: one tablet will be inserted daily for 14 days
Trial: NCT00410228
Drug: AHT956
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00240227
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01692171
Drug: Heparin, Low-Molecular-Weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single intravenous administration of 3mg/Kg of the test drug and the comparator drug, according to randomization, in a crossover design, each administration separated by 6 days of washout.
Trial: NCT02144584
Drug: Placebo (for memantine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to be capsuled to look identical to active drug (memantine)
Trial: NCT04190173
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1/2-1 tablet once daily enteral feeding for 5 consecutive days
Trial: NCT03833388
Drug: TOP1630 0.1% Ophthalmic Solution TID OU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral ocular drug administration
Trial: NCT03833388
Drug: Placebo to TOP1630 0.1% Ophthalmic Solution TID OU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral ocular drug administration
Trial: NCT03530800
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 10 weeks
Trial: NCT02963935
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously (s.c., under the skin) once daily for 56 weeks. Dose gradually increased to 3.0 mg
Trial: NCT02273531
Drug: Asasantin ER, new formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02273531
Drug: Asasantin ER, present commercial formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02337738
Drug: TVP-1012 1mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TVP-1012 1mg Tablets
Trial: NCT02337738
Drug: TVP-1012 0.5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TVP-1012 0.5mg Tablets
Trial: NCT02337738
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Tablets
Trial: NCT00130676
Drug: matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daily for 7 days
Trial: NCT02649231
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline
Trial: NCT00437281
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03208959
Drug: HTI-1090
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDO/TDO inhibitor
Trial: NCT01875445
Drug: Inositol
RxNorm normalized name: Inositol
DrugBank: Inositol (DB13178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Taken as 2g of powder TID for 2 weeks, then 4g of powder TID for 2 weeks and then 6g of powder TID for the remainder of the study.
Trial: NCT01875445
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taken as 2g of powder TID for 2 weeks, then 4g of powder TID for 2 weeks and then 6g of powder TID for the remainder of the study.
Trial: NCT02103647
Drug: Immediate release capsule(lyrica 150mg * 2/day)
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate release capsule
Trial: NCT02103647
Drug: sustained release tablet
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sustained release tablet